Indian Government In Dilemma As DCGI's Competence Is Questioned Amid Mounting Criticism
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - An eerie uncertainty looms over the future of India's highest and most powerful drug authority, the Drug Controller General of India, as the government was challenged last week against its decision to grant a nine-month service term extension to the present incumbent Surinder Singh
You may also be interested in...
Graft Charges At India State Drug Controller’s Office Lead To Multiple Transfers
As news of fresh corruption charges cloud efforts for transparency in India’s licensing process, several high-profile officials are learned to have been moved in a brisk clean-up exercise by the health ministry.
Powerful Parliamentary Committee Slams India’s Drug Regulator; Calls For Swift Overhaul
The committee unravels a system full of questionable practices and recommends complete overhaul of India’s drug regulator.
R&D Funding, Epidemiology And Balanced Policies To Fuel India Growth - CII Lifescience Conclave
NEW DELHI - Establishment of a new global disease detection center for epidemiology studies in India, a unique government funding method to boost innovation, and academic partnerships were among the prominent discussion topics at the Annual LifeScience Conclave, organized by the Confederation of Indian Industry in the capital city